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Abstract
Introduction Observational healthcare data contain
information useful for hastening detection of adverse drug
reactions (ADRs) that may be missed by using data in
spontaneous reporting systems (SRSs) alone. There are
only several papers describing methods that integrate evi-
dence from healthcare databases and SRSs. We propose a
methodology that combines ADR signals from these two
sources.
Objectives The aim of this study was to investigate whe-
ther the proposed method would result in more accurate ADR
detection than methods using SRSs or healthcare data alone.
Research Design We applied the method to four clini-
cally serious ADRs, and evaluated it using three experi-
ments that involve combining an SRS with a single facility
small-scale electronic health record (EHR), a larger scale
network-based EHR, and a much larger scale healthcare
claims database. The evaluation used a reference standard
comprising 165 positive and 234 negative drug–ADR pairs.
Measures Area under the receiver operator characteristics
curve (AUC) was computed to measure performance.
Results There was no improvement in the AUC when the
SRS and small-scale HER were combined. The AUC of the
combined SRS and large-scale EHR was 0.82 whereas it was
0.76 for each of the individual systems. Similarly, the AUC
of the combined SRS and claims system was 0.82 whereas it
was 0.76 and 0.78, respectively, for the individual systems.
Conclusions The proposed method resulted in a signifi-
cant improvement in the accuracy of ADR detection when
the resources used for combining had sufficient amounts of
data, demonstrating that the method could integrate evi-
dence from multiple sources and serve as a tool in actual
pharmacovigilance practice.
Key Points
Observational healthcare data can complement
spontaneous reporting systems in signal detection
through quantitative integration of source-specific
signal scores.
Signal detection predictive accuracy from each
source can be improved by combining signals across
sources.
1 Introduction
Adverse drug reactions (ADRs) are known to cause high
morbidity and mortality and cost several billion dollars
annually [1–3]. In addition to the ADRs detected during
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pre-marketing clinical trials, unanticipated ADRs may
occur after a drug has been approved, attributable to its use,
which may be prolonged, on large, diverse populations [4].
Therefore, the post-marketing surveillance of drugs is
essential for generating more complete drug safety profiles
and for providing a decision-making tool to help govern-
mental drug administration agencies take an action on the
marketed drugs [5, 6].
Analysis of spontaneous reports of suspected ADRs has
traditionally served as a valuable tool in the detection of
previously unknown ADRs in post-marketing surveillance
[7, 8]. Spontaneous reporting systems (SRSs) can be
effective in revealing unusual or rare adverse events that
occur with the initial use or short-term use of medications
[9]. However, SRSs do not rapidly lead to ADR detection if
the adverse event is relatively common but not necessarily
drug-related in the general population, and SRSs are also
known for limitations such as under-reporting and biased
reporting influenced by media coverage or the length of
time on the market [10–12]. Electronic healthcare data,
such as electronic health records (EHRs) and administra-
tive claims data, are starting to be used to complement
SRSs [13–16]. Electronic healthcare data contain longitu-
dinal patient information collected during routine clinical
care, and have been used extensively in pharmacoepi-
demiology and pharmacoeconomics to study the natural
history of disease and treatment utilization. Another
opportunity for these data is to study the prevalence of a
drug and an ADR, to explore the temporal relationship
between exposure and outcome, and to reduce the reporting
biases of SRSs. The appropriate use of healthcare data has
the potential for earlier detection of drug safety signals
before healthcare professionals report them to an SRS
system [17]. With the ongoing development of the US
Food and Drug Administration’s (FDA’s) Sentinel Initia-
tive and similar systems around the world, near real-time
active pharmacovigilance may soon be a reality [18]. Since
the Sentinel system is based on administrative claims data
captured as part of the reimbursement process surrounding
routine clinical care, its value can be considered ‘comple-
mentary’ to the utility of SRSs. However, electronic
healthcare data has its own limitations, which are different
from the SRS limitations, since healthcare data usually
mention the patient’s medications, symptoms, and diseases
individually without mentioning explicit causal relation-
ships, such as the indications for prescribing the
medications.
Therefore, statistical methods, together with the use of
temporality, are needed to infer an estimate of the strength
of associations, without the benefit of an explicit reported
ADR relationship. For example, a statistical association
between a medication and a condition may be a treatment if
the condition precedes the medication event, an ADR only
if the condition follows the medication event, or an indirect
association stemming from another event (e.g., a con-
founder). Considerable systematic studies of the potential
value of these databases in post-marketing pharmacovigi-
lance have been undertaken by the Observational Medical
Outcomes Partnership (OMOP, http://omop.org) [16, 19,
20] and the European Union project Exploring and
Understanding Adverse Drug Reactions (EU-ADR, http://
euadr-project.org) [21].
Currently, research efforts are starting to focus on the
use of multiple data sources, such as SRSs, electronic
healthcare data, biomedical literature, and chemical infor-
mation, to detect and validate novel ADRs. For example,
Tatonetti et al. discovered a potentially new drug interac-
tion, which can lead to unexpected increases in blood
glucose levels, between paroxetine and pravastatin based
on SRSs, and then validated this interaction using multi-
center EHRs [22]. Duke et al. predicted probable novel
myopathy-associated drug interactions based on the liter-
ature, and evaluated them using a large EHR database [23].
Vilar et al. re-ranked the ADR signals mined from a large-
scale claims database using 2D structure similarity [24].
However, the above studies have used a single data
resource to generate ADR signals and then have indepen-
dently used another resource for validation or enrichment
analysis. Harpaz et al. recently proposed a Bayes model to
computationally combine a disparate SRS and a healthcare
claims database, and the performance was shown to have
promising results based on a reference standard provided
by OMOP [25].
In addition to the large-scale claims and EHR databases
used by the OMOP and EU-ADR projects, individual
EHRs were shown to have potential for diverse types of
studies, including pharmacovigilance, drug re-purposing
and phenome-wide association scans (PheWAS) [26–28].
Our group conducted several studies based on the EHR
from New York Presbyterian Hospital at Columbia
University Medical Center (NYP/CUMC), and demon-
strated its potential for drug safety studies. Additionally,
we demonstrated that when using the EHR, confounding is
one of the most important challenges that needs to be
handled [14, 29–31]. Confounding is also an important
issue when using the SRS databases. The main algorithm
for detecting ADRs in SRSs is an approach referred to as
disproportionality analysis, which compares the number of
observed cases with that of expected cases [7]. Detecting
ADRs in SRSs is challenging partly due to under-reporting
of unexpected events, the lack of a priori knowledge and a
bias towards well publicized ADRs [32]. Thus, there is an
inherent tradeoff when detecting new ADRs by taking
advantage of primary suspected information based on
experts’ intuition which may be biased, possibly leading to
delayed ADR detection, or detecting ADRs by considering
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concomitant medications as co-occurrence information,
possibly leading to false positive signals. Several previous
studies showed that multivariate logistic regression is
helpful to guard against false positive signals due to con-
founding by concomitant drugs [33, 34].
Although both SRS and healthcare data represent
unique challenges in their use, we believe that they
complement each other along several dimensions that may
improve pharmacovigilance [17, 25]. A challenge
accompanied by the richness of information for pharma-
covigilance practice occurs when these two resources
provide conflicting or inconsistent information. There-
fore, we propose a methodological framework to integrate
analyses generated from the FDA Adverse Event
Reporting System (FAERS) and from healthcare data. As
part of the methodological framework, we incorporated a
method to deal with confounding effects in NYP/CUMC
EHR and the FAERS. We applied the method to four
clinically serious ADRs: acute renal failure (ARF), acute
liver injury (ALI), acute myocardial infarction (AMI), and
upper gastrointestinal bleeding (GIB) [35] with an aim of
demonstrating that signal discrimination performance can
be improved by such an integrative strategy. Predictive
accuracy, as measured by the area under receiver oper-
ating characteristics curve (AUC), is a means of esti-
mating the degree of discrimination of a signal detection
system and is used as an evaluation metric in this study.
We tested our integrative method using the following
three different experiments so that we could also explore
the effect of data size and bias on the method: (i) where
we combined FAERS with a single small-scale EHR
database NYP/CUMC, (ii) where we combined FAERS
with a large-scale network-based EHR database, and (iii)
where we combined FAERS with a much larger-scale
claims database. We further evaluated our system under




2.1.1 FDA Adverse Event Reporting System (FAERS)
The data were extracted from FAERS from 2004 to 2010,
which comprised case reports mainly reported from phar-
maceutical manufacturers and, to a lesser extent, from
healthcare professionals and consumers [36]. We prepro-
cessed and mapped the free-text drug names to their
ingredient level specification using the STITCH (Search
Tool for Interactions of Chemicals) database [37]. The
ADRs in FAERS were already coded using MedDRA
preferred terms [38]. In this study, we did not utilize the
explicit relationships between drugs and ADRs and con-
sidered all relationships as co-occurrence information.
Consequently, we extended data to all medications men-
tioned in the case reports including primary suspected,
secondary suspected and concomitant medications, as well
as indications. The signals from FAERS were obtained
using the confounding adjustment method, which is pre-
sented below.
2.1.2 New York Presbyterian Hospital at Columbia
University Medical Center (NYP/CUMC) Electronic
Health Record (EHR)
The data were extracted from the single-hospital EHR
system at NYP/CUMC, after institutional review board
approval. The data consisted of retrospective narrative
records of inpatient and outpatient visits from 2004 to
2010, including admission notes, discharge summaries, lab
tests, structured diagnosis in the form of International
Statistical Classification of Diseases, Version 9 (ICD-9)
codes and structured medication lists, and the majority of
the data available for this study were from an inpatient
population. Narrative reports were used to obtain the
patients’ medications, and the structured ICD-9 diagnosis
codes were used to detect ADR events; these codes also
served as surrogates of patient characteristics for con-
founding adjustment analysis. Similar to FAERS, the sig-
nals from the EHR were computed using the confounding
adjustment method proposed in this study.
2.1.3 GE EHR
The EHR database, GE MQIC (Medical Quality
Improvement Consortium) (a GE Healthcare data consor-
tium), represents a longitudinal outpatient population, and
captures events in structured form that occur in usual care,
including patient problem lists, prescriptions of medica-
tions, and other clinical observations as experienced in the
ambulatory care setting. The data were analyzed system-
atically under OMOP using seven commonly used methods
for 399 drug–ADR pairs [19]. The resulting signal scores
are reported and publicly available in OMOP. The signal
scores for this database were computed using the optimal
analytic method for each outcome as follows: self-con-
trolled case series (SCCS) method for ARF (analysis-ID
1949010), self-controlled cohort (SCC) method for ALI
(analysis-ID 409002), and information component tempo-
ral pattern discovery (ICTPD) method for AMI and GIB
(analysis-IDs 3016001 and 3034001) [19].
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2.1.4 Claims Data
In this study, we obtained signal scores associated with the
largest claims database—MarketScan Commercial Claims
and Encounters (CCAE). Similar to the GE data, CCAE
data were extensively analyzed in OMOP for the same
drug–ADR pairs with various methods. The signal scores
we used for this database were computed by OMOP using
the SCC method for ARF, ALI and AMI (analysis-IDs
404002, 403002 and 408013), and the SCCS method for
GIB (analysis-ID 1931010) [19].
2.1.5 Reference Standard
The reference standard was developed by OMOP. It con-
tains 165 positive and 234 negative controls, i.e., drugs for
which there is or is no evidence for corresponding ADRs.
This reference set was established by OMOP based on
natural language processing (NLP) of structured product
labels, systematic search of the scientific literature, and
manual validation. The reference standard comprises 181
drugs and four clinically important ADRs: ARF ALI, AMI,
and GIB. More details about the reference standard data
collection, including drug names, can be found in a pre-
vious publication [39].
Other important research conducted by OMOP resulted
in establishment of varied definitions, from narrow to
broad, for each ADR outcome they studied [34, 40]. Fur-
thermore, the mapping between ICD-9 codes and corre-
sponding MedDRA codes for each ADR outcome were
also made available by OMOP. We adopted these defini-
tions to identify ADR case groups in NYP/CUMC EHR
and in FAERS.
2.2 Cohort Identification
In this study, we used the broad definitions of ICD-9 codes
established by OMOP for identifying ADR events in NYP/
CUMC EHR [40]. The same definitions were also utilized
in the GE EHR and the claims database. In addition, we
used the corresponding MedDRA codes (as determined
by OMOP) for FAERS to identify patients with a particular
ADR. Our aim was to ensure that the ADRs are equivalent
when using the different databases.
2.2.1 FAERS
Case reports, which have at least one applicable ADR
MedDRA code for an ADR, were identified as a case
group, whereas the rest were used as a control group. The
indications and all the medications reported in case reports
were included as candidate covariates for confounding
assessment.
2.2.2 NYP/CUMC EHR
The four ADR case groups were identified using their
equivalent ICD-9 codes. For each ADR, the control group
consisted of those patients free of the particular ADR. A
patient may have multiple records in an EHR and therefore
may have experienced an ADR several times, and may
have been on and off a particular medication. Only the first
occurrence of an ADR was considered and candidate
medications were restricted to those that were mentioned
before the ADR. If a case patient did not have any medi-
cations mentioned before the ADR, or a control patient did
not have any medication recorded before 2010, they were
excluded from the analysis. We also applied a 180-day
window before the latest medication prior to the ADR to
retrieve medications and medical conditions (ICD-9 diag-
nosis codes). We assumed that anything prior to that win-
dow was unlikely to be associated with the ADR. For
example, a drug taken in 2004 unlikely leads to the
development of an ADR in 2010. For the control groups,
we used the latest medication record before December 31,
2010 as the anchor, and retrospectively drew a 180-day
window to select medications and ICD-9 diagnoses. Since
our patient population was dominated by inpatients with
single hospitalization, the individual studying windows in
the control groups were evenly distributed from 2004 to
2010. Only ICD-9 codes were included as possible con-
founder candidates. Figure 1 illustrates the data extraction
windows for cases and controls.
2.3 Methodology Framework
As illustrated in Fig. 2, our methodology comprises three
steps: (i) obtaining the confounding adjusted signal score
for each drug–ADR pair from individual health data; (ii)
calibrating the signal scores based on the empirical distri-
bution derived from a set of reference negative controls;
(iii) combining calibrated signal scores from disparate
databases. In what follows, we elaborate the technical
details in each of the three steps.
2.3.1 Obtaining Confounding-Adjusted ADR Signal Scores
This step was based on a previously published work con-
ducted by our group which included identifying con-
founders for specific medications using marginal odds
ratios (ORs) and estimating the drug–ADR associations
using a least absolute shrinkage and selection operator
(LASSO) type regularization [31]. Results showed that the
method outperformed the high-dimensional propensity
score method, but the resulting false positive rates still
exceeded the nominal level [31]. Therefore, we revised the
method in two aspects. (1) In the previous work, we only
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considered the potential confounders that were signifi-
cantly and positively associated with both the ADR and the
medication. We now expanded this list to include medical
conditions that were significantly associated with the ADR
and medication in either a positive or negative direction.
The rationale is that negatively associated conditions could
also bias the strength of association. (2) Standard LASSO
implicitly assumes a sparse structure in the covariates, and
hence tends to select insufficient confounders in high-di-
mensional regression, which in turn leads to an inflated
false positive rate. We adopted a two-step LASSO [41] for
a better control of the false positive rate. In the first step,
we used the standard logistic LASSO regression to select
the confounders that are associated with ADR after
accounting for the impact from the drug use. In the second
step, we used a weighted linear LASSO regression to select
the covariates that are associated with the drug use. We
then estimated the conditional association between the
ADR and drug adjusting for all the confounders selected in
both steps. It is shown that the type I error could be well
controlled by including the confounders from both models
[41]. Finally, we used one-sided p values of the adjusted
log ORs as the signal scores. The details for the two-step
LASSO are shown in the electronic supplementary mate-
rial, Box 1. For GE EHR and claims data, the signal scores
(one-sided p values) were generated based on the log rel-
ative risks (log RRs) and their standard errors provided by
their optimal methods.
2.3.2 Calibrating ADR Signal Scores Based on a Set
of Reference Negatives
If there is no drug–ADR association, the signal scores
using one-sided p value should be uniformly distributed
over the interval (0, 1) in theory. In reality, that is often
deviated and leads to an inflated false discovery rate. We
apply the estimation algorithm to a set of negative con-
trols in the reference standard, and estimate the empirical
distribution of resulting signal scores following formula
(1), where qi represents a one-sided p value of a negative
control and n represents the number of negative controls
in the reference standard. F^n xð Þ is then used as the null
distribution to calibrate signal scores. This calibration was
ADR specific by assuming that signal scores within sim-
ilar groups have their inherent ranking. For example, a
negative control for ALI was not considered in the cali-
bration of AMI. This procedure could be considered as a
supervised training procedure with the training set con-
sisting of negative controls in the reference standard.
Since we did not use the overall reference standard for
both training data and testing data, over-fitting is less of a
problem.
Fig. 1 Electronic health record
(EHR) cohort identification and
candidate covariates selection.




Fig. 2 Methodological framework. ADR adverse drug reaction,
CCAE MarketScan Commercial Claims and Encounters, EHR Elec-
tronic health record, FAERS FDA Adverse Event Reporting System,
GE EHR GE Healthcare MQIC (Medical Quality Improvement
Consortium) database, NYP/CUMC New York Presbyterian Hospital
at Columbia University Medical Center, OMOP Observational
Medical Outcomes Partnership
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2.3.3 Combining ADR Signal Scores from Two
Heterogeneous Databases
Let pi1 denote the ith ADR signal score computed from
source 1, for example, the NYP/CUMC EHR, and pi2
denote the signal score for the same drug–ADR pair
computed from source 2, for example, the FAERS. We
used the formula (2) to combine the signal scores from the
two data sources.
2  log pi1ð Þ þ log pi2ð Þ½   v24ð Þ under the null hypothesis
ð2Þ
2.4 Evaluation Design
We used the reference standard developed by OMOP as
described above to generate three reference standards for our
study. For reference standard 1, we restricted the evaluation
to those drug–ADR pairs for which FAERS contained at least
one case report and the NYP/CUMC EHR contained at least
five patients who were exposed to the studied medications
and who were later diagnosed with the studied ADR. The
application of a case count threshold is to ensure numeric
stability in the signal detection estimates, consistent with
what is proposed by Bate and Evans, in the use of PRR
(proportional reporting ratio) as signal detection routine for
SRS alone [7]. For reference standard 2, we restricted the
evaluation to those drug–ADR pairs for which FAERS had at
least one case report and the GE EHR had results available in
the OMOP result set. We had the same restriction for refer-
ence standard 3 based on FAERS and CCAE claims data. The
details of these three reference sets are shown in Table 1.
Based on reference set 1, 2 or 3, the performance of the
combined system was compared against the performance
of signal scores generated by each data source
independently. Performance was measured using the AUC.
To test if the differences of AUCs based on the different
combination systems were statistically significant, we
computed a one-sided p value for the hypothesis that the
difference between the AUC of the two systems was not
equal to 0. The tests were computed using a bootstrapping
method [42, 43]. To ensure the p values were computed
based on large enough samples of signal scores, and to get
a single answer representing all outcomes, the significant
tests were based on overall reference sets used in each
experiment.
We further studied the nature and proper use of the
combined system on the basis of four scenarios that could
occur in actual pharmacovigilance practice, and which
clinical assessors deal with frequently in their routine work.
Using the cutoff p value of 0.05, we defined a drug–ADR
pair as a signal if its p value is\0.05. Accordingly, the four
scenarios are: (i) a drug–ADR pair has p value \0.05 in
both FAERS and healthcare databases meaning a consis-
tent signal is exhibited in both sources; (ii) a drug–ADR
pair has p value C0.05 in both data sources meaning the
lack of this signal in either source; (iii) a drug–ADR signal
appears in FAERS but not in healthcare database meaning
an inconsistent signal is exhibited; and (iv) a drug–ADR
signal appears in healthcare database but not in FAERS,
also meaning an inconsistent signal is exhibited.
We also compared the AUC before and after con-
founding adjustment on the basis of the FAERS and NYP/
CUMC EHR, respectively. Furthermore, we identified false
positive signals in NYP/CUMC EHR by selecting those
negative controls that produced a one-sided p value\0.05
in the confounding adjustment analysis. We identified false
negative signals in EHR by selecting those positive con-
trols that had a one-sided p value[0.05 in the confounding
adjustment analysis. In addition, we compared the AUC
performance of the confounding adjustment method with
the cutting-edge method Gamma Poisson Shrinkage (GPS)
that produces signal scores signified by lower 5th
Table 1 Subsets of the OMOP reference standard used in the three experiments
Reference Set 1
FAERS and NYP/CUMC EHR
Reference Set 2
FAERS and GE EHR
Reference Set 3
FAERS and claims data
P N P N P N
Acute renal failure 16 37 21 48 21 51
Acute liver injury 52 16 75 30 77 32
Acute myocardial infarction 10 28 33 51 33 58
Upper GI bleed 17 38 24 57 24 63
Total 95 119 153 186 155 204
EHR electronic health record, FAERS FDA Adverse Event Reporting System, GE EHR GE Healthcare MQIC (Medical Quality Improvement
Consortium) database, N negative controls, NYP/CUMC New York Presbyterian Hospital at Columbia University Medical Center, OMOP
Observational Medical Outcomes Partnership, P positive controls in the reference standard
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percentile of the posterior observed-to-expected distribu-
tion (EB05) on the basis of FAERS data. We restricted
evaluation to those drug–ADR pairs for which FAERS had
at least one case report. Furthermore, we assigned a signal
score value of 0, the lowest possible signal score for EB05,
to those drug–ADR pairs that were never mentioned as
primarily suspected relationships, and consequently not
included in the analysis using GPS.
3 Results
We used 2.7 million case reports from FAERS, 0.3 million
patients from the NYP/CUMC EHR, 11 million patients
from the GE EHR data, and 47 million patients from the
CCAE claims data. Some case reports were excluded in
FAERS due to typos of drug names and/or the incomplete
list of drug names using STITCH. The characteristics of
patients for the four databases are shown in Table 2.
FAERS has the oldest population while CCAE has the
youngest population. The ratio of males to females is
approximately 1:1 for CCAE while other databases have
more females than males, and among them FAERS has the
largest number of females.
Table 3 shows the AUCs with and without confounding
adjustment, which suggests that the confounding adjust-
ment was essential for both FAERS and NYP/CUMC EHR
individually. The AUCs after the confounding adjustment
in FAERS were statistically significantly better (e.g.,
higher) than those without the adjustment based on refer-
ence set 1. However, we did not observe a substantial
improvement in the NYP/CUMC EHR. In total, there were
four false positive signals and 35 false negative signals for
the NYP/CUMC EHR. We displayed them correspondingly
in electronic supplementary material Table S1 and
Table S2.
The results from experiment 1 are presented in Table 4.
We found that the FAERS system performed significantly
better than the NYP/CUMC EHR system. Combining
FAERS and NYP/CUMC EHR data did not improve the
ADR detection performance of FAERS, although it did not
harm it either. The combined system also performed sig-
nificantly better than the NYP/CUMC alone. Experiment 2,
which is also presented in Table 4, shows that the com-
bined system outperformed both the FAERS and the GE
EHR individual systems. Improvements were observed for
all the outcomes, although at different levels. The AUC of
the combined system ranged from 76 % for ALI to 92 %
for ARF. For individual systems, the AUC performance of
the GE EHR system was better for AMI, but worse for
ARF, ALI, and GIB, compared with FAERS. Similar
results were found when combining FAERS with the
CCAE in experiment 3. The CCAE had better performance
than FAERS for AMI and GIB, but was worse for the other
two. Again, the combined system outperformed the indi-
vidual ones for all the four outcomes.
Table 2 Demography for four databases
Database Population
FAERS Total: 2.7 m; male: 37 %; mean age (SD): 53.0 (20.3)
NYP/
CUMC
Total: 0.3 m; male: 42 %; mean age (SD): 43.6 (27.0)
GE Total: 11.2 m; male: 42 %; mean age (SD): 39.6 (22.0)
CCAE Total: 46.5 m; male: 49 %; mean age (SD): 31.4 (18.1)
CCAE MarketScan Commercial Claims and Encounters, FAERS
FDA Adverse Event Reporting System, GE GE Healthcare MQIC
(Medical Quality Improvement Consortium) database, NYP/CUMC
New York Presbyterian Hospital at Columbia University Medical
Center
Table 3 AUC for FAERS and
NYP/CUMC EHR before and
after confounding adjustment
ADR FAERS NYP/CUMC EHR
Unadjusted Adjusted Unadjusted Adjusted
Acute renal failure 0.50 0.89* 0.58 0.61
Acute liver injury 0.50 0.70* 0.55 0.45
Acute myocardial infarction 0.48 0.65* 0.44 0.53
Upper GI bleed 0.49 0.83* 0.48 0.54
Total 0.49 0.75* 0.55 0.51
Unadjusted: signal scores (one-sided p values) are not adjusted for the confounding effect
Adjusted: signal scores (one-sided p values) are adjusted for the confounding effect
The bold values indicate the highest AUC performance but not necessarily significantly higher than
comparators except for those also marked with * where the performance difference is statistically
significant
ADR adverse drug reaction, AUC area under the receiver operator characteristics curve, EHR Electronic
health record, FAERS FDA Adverse Event Reporting System, NYP/CUMC New York Presbyterian
Hospital at Columbia University Medical Center
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Results in Table 5 show that the combined system
achieved better AUC performances in most of four sce-
narios for two of the combination studies. Overall, the
combined system had an increase in AUC when compared
to the individual systems where the increase ranged from
3 % to 11 %, but there was one exception. The exception
occurred in one scenario where the AUC was higher when
using the claims database alone in the situation where the
signals were detected in FAERS but not in the claims
database. The difference in AUC performance was defined
as the AUC of the combined system minus the AUC of the
better performing individual system.
Using the cutoff p value of 0.05, we evaluated the pre-
cision and recall of the two combined systems—the com-
bination system using FAERS and GE EHR, and the
combination system using FAERS and claims data. Com-
bining FAERS with the GE EHR resulted in higher recall
(0.41 versus 0.35), while the precisions of the two com-
bination systems were almost identical (0.925 versus
0.931). Using the same cutoff p value, eight more signals
were only detected by the combined system using FAERS
and GE EHR, as shown in Table 6. Among them, seven of
the eight were true positive signals.
Figure 3 shows the histograms of the signal scores for
GIB in each experiment. It is apparent from the figure that
the scale of signal score for FAERS did not overlap
substantially with each healthcare data set, and the dis-
tribution of the signal scores did not follow a normal
distribution.
4 Discussion
The main results of our evaluation show that combining
signals from two relatively large data sources (e.g., FAERS
and the GE EHR data, FAERS and the CCAE claims data)
using the proposed methodological framework led to an
overall significant improvement, which was replicated for
the different outcomes. However, we did not observe the
improvement when combining FAERS with the NYP/
Table 4 AUC of signal detection performance for FAERS, healthcare data, and combined systems
ADR Experiment 1. Combining FAERS and NYP/CUMC EHR
FAERS EHR Combined
Acute renal failure 0.89 0.61 0.89
Acute liver injury 0.70 0.45 0.68
Acute myocardial infarction 0.65 0.53 0.70
Upper GI bleeding 0.83 0.54 0.83
Total 0.75 0.51 0.74
ADR Experiment 2. Combining FAERS and GE EHR
FAERS GE Combined
Acute renal failure 0.91 0.68 0.92
Acute liver injury 0.71 0.63 0.76*
Acute myocardial infarction 0.72 0.80 0.82
Upper GI bleeding 0.80 0.77 0.87*
Total 0.76 0.76 0.82*
ADR Experiment 3. Combining FAERS and the claims data
FAERS Claims Combined
Acute renal failure 0.91 0.83 0.93
Acute liver injury 0.72 0.69 0.79*
Acute myocardial infarction 0.71 0.77 0.82*
Upper GI bleeding 0.81 0.83 0.86
Total 0.76 0.78 0.82*
The bold values indicate the highest AUC performance but not necessarily significantly higher than comparators except for those also marked
with * where the performance difference is statistically significant
ADR adverse drug reaction, AUC area under the receiver operator characteristics curve, EHR Electronic health record, FAERS FDA Adverse
Event Reporting System, GE EHR GE Healthcare MQIC (Medical Quality Improvement Consortium) database, NYP/CUMC New York
Presbyterian Hospital at Columbia University Medical Center
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CUMC EHR. The discrepancies are possibly attributed to
issues such as small data size and sample biases.
4.1 Small Data Size
NYP/CUMC EHR has already been successfully used for
detecting safety signals in several studies [13, 44, 45].
However, challenges remain because of the relatively small
size of the data. There were only 0.3 million patients in
NYP/CUMC EHR compared with 11 million in GE EHR
and 47 million in the CCAE claims data. Since ADRs
generally occur infrequently in the EHRs, and their signals
are often weak, a large data size is essential for effective
detection.
For the same reason, we could clearly observe that
higher prevalence of an ADR resulted in better
performance on the basis of the NYP/CUMC EHR.
Specifically, NYP/CUMC EHR included 14,890 patients
with ARF, 6099 patients with ALI, 5817 patients with
AMI, and 6683 patients with GIB. ARF, with many more
patients (almost three times as many patients as those
developing AMI), had better AUC performance than the
other three ADRs. Furthermore, when using NYP/CUMC
EHR to detect the drugs associated with ARF, we achieved
100 % precision, and successfully identified three true
positive medications: hydrochlorothiazide, telmisartan, and
candesartan.
4.2 Sampling Biases
The NYP/CUMC EHR data came from a tertiary care
academic medical center in a major metropolitan inner city
Table 5 The AUC performance of FAERS, healthcare data and the combined system on the basis of four scenarios













signal but FAERS does
not
Positive/negative controlsa 25/0 61/152 29/11 38/23
FAERS alone NA 0.71 0.73 0.60
GE alone NA 0.69 0.78 0.68
FAERS and GE combined NA 0.75* 0.89* 0.68
Positive/negative controlsa 49/3 16/104 7/8 83/89
FAERS alone 0.84 0.68 0.68 0.67
Claims alone 0.69 0.50 0.86 0.67
FAERS and claims combined 0.89* 0.74* 0.79 0.68
Signals are identified based on one-sided p value\0.05
The bold values indicate the highest AUC performance but not necessarily significantly higher than comparators except for those also marked
with * where the performance difference is statistically significant
AUC area under the receiver operator characteristics curve, FAERS FDA Adverse Event Reporting System, GE GE Healthcare MQIC (Medical
Quality Improvement Consortium) database, NA AUC performances are not computable when only positive controls are available
a Positive and negative controls are defined according to the reference standard
Table 6 ADR signals detected
only using the combined GE
and FAERS system and their
one-sided p values in three
systems
Medication ADR Ground Truth FAERS GE Combined system
Piroxicam ARF 1 0.299 0.432 0.043
Amoxapine AMI 1 0.076 0.118 0.007
Diflunisal AMI 1 0.109 0.192 0.007
Eletriptan AMI 1 0.682 0.072 0.034
Nabumetone AMI 1 0.079 0.494 0.035
Nelfinavir AMI 0 0.292 0.263 0.044
Zolmitriptan AMI 1 0.224 0.381 0.034
Ketorolac GIB 1 0.425 0.069 0.041
ADR adverse drug reaction, AMI acute myocardial infarction, ARF acute renal failure, FAERS FDA
Adverse Event Reporting System, GE GE Healthcare MQIC (Medical Quality Improvement Consortium)
database, GIB upper gastrointestinal bleeding, NYP/CUMC New York Presbyterian Hospital at Columbia
University Medical Center
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area, which may have led to a highly skewed population. In
addition, many of the patients included in our analysis
could have been referred from other facilities and therefore
their EHR data may have been incomplete because it may
have lacked longitudinal information for many of those
patients. Specifically, only 37 % of patients had at least one
outpatient visit and only 14 % of patients had more than
one visit. The NYP hospital does have an in-house for-
mulary, which is applicable only to medications concerning
inpatients. However, the medications studied in this work
were mainly home medications and were not related to the
NYP hospital formulary. Moreover, NYP/CUMC EHR
data was not linked to pharmacy prescriptions or refills, and
the medications extracted from free-text notes were just
mentions of medications, and therefore temporal relation-
ships between medication exposures and ADR events may
not have been definitive. In contrast, the GE EHR repre-
sented a large outpatient population and captured longitu-
dinal patient information, such as ICD-9 coded medical
problems and prescriptions. NYP/CUMC represented an
inpatient data source and GE EHR represented a strictly
outpatient data source, both of which could not capture the
complete patient information, and therefore the rates of
ADRs might be underestimated. The claims data repre-
sented a much larger and more diverse population, and
captured longitudinal patient information including diag-
nosis codes for billing purposes, as well as dates when
prescriptions were filled or refilled. However, both the GE
EHR and the claims data may also have faced the challenge
of a skewed patient population, such as sicker patients
having many more visits, and more prescriptions and refills
in the database [46].
4.3 Usefulness for Pharmacovigilance Practice
The AUC evaluation showed that FAERS had substantially
better performance for ARF and ALI, and worse perfor-
mance for AMI than healthcare data, which indicates that
Fig. 3 Histograms of signal scores when combining FAERS with the
three healthcare data sets. Signal scores for FAERS and the EHR are
signified by log odds ratio, and signal scores for the GE EHR and the
claims data are signified by log relative risks. EHR Electronic health
record, FAERS FDA Adverse Event Reporting System, GE EHR GE
Healthcare MQIC (Medical Quality Improvement Consortium)
database, NYP/CUMC New York Presbyterian Hospital at Columbia
University Medical Center
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no single source may provide best evidence for all ADR
detections. Therefore, synthesis of evidence from multiple
streams of information is extremely significant. Currently,
clinical assessors carry out the analysis of evidence from
multiple sources. For example, clinical assessors may
validate or want to evaluate a signal from different
resources, such as those generated from SRSs and/or
healthcare data. Thus, a common situation that clinical
assessors need to deal with is inconsistent or conflicting
information from the different data sources.
Results show that the combined ADR signals generated
by the proposed method improved the AUC performance
significantly compared with individual systems. In addition,
we evaluated the combined system in four scenarios men-
tioned above. We observed that the consistent improvement
was achieved by the combined system except for signals that
appeared in FAERS but not in the CCAE claims database.
However, the combined system was still better than the
FAERS system alone in ranking potential signals. Therefore,
the proposed system could serve as a tool for clinical
assessors when they review ADR cases. For example, in the
scenario of consistent signals, clinical assessors are likely to
believe the existence of the signals and may want to select
the strongest signals for further assessment; the combined
system could prioritize signals by integrating the two sour-
ces. In the scenario of inconsistent signals, the combined
system is able to resolve inconsistent or conflicting statistical
information and then provide a single response through the
consolidation of statistical information from the two sources.
In the scenario where no single source provides a signal, the
combined system could possibly transfer two relatively
weak signals into a strong composite one. For instance, eight
more signals were detected only using the combined GE and
FAERS system and seven of them were true positives,
which is promising. However, a practical challenge is how
to effectively communicate these results to the clinical
assessors. In addition, combining FAERS with GE resulted
in higher recall and almost identical precision when com-
pared with combining FAERS with claims data. These
results further demonstrated that the larger data size (e.g.,
combining FAERS with claims) does not necessarily lead to
more sensitive ADR detection. We also observed that
healthcare databases were more sensitive for ADR detection
than FAERS in that more signals were identified. We
acknowledge that the recall and precision are threshold-de-
pendent performance metrics. Hence, the results may vary
when using different thresholds. In practice, pharmacovigi-
lance requires the successful integration of quantitative
measures of population-level summaries with clinical adju-
dication and insights that derive from patient-level case
review. The true utility of this approach will only be
determined through implementation into the workflow of
current pharmacovigilance operations.
4.4 Related Work
Our method was designed originally to combine the NYP/
CUMC EHR with FAERS, which is the first such study.
Harpaz et al. designed an empirical Bayes model to com-
bine signals across FAERS and claims data showing its
effectiveness using the same reference standard used in this
study [25]. However, that method required that the data
satisfy two assumptions: (a) the signal scores generated
from each individual data source should be on approxi-
mately the same scale, and (b) the scores should follow the
log normal distribution. Our data sets did not meet these
assumptions. Figure 3 illustrates the violation of the above
two assumptions for GIB, but the other three ADRs had
similar results.
4.5 Methods to Deal with Confounding
The capability to reduce or eliminate confounding is a
major aim of ADR detection. Self-controlled designs have
recently been proposed and successfully utilized in ADR
detection based on longitudinal healthcare data. They
attempt to identify equivalent periods of unexposed time
within the same patients, against which to compare the
same patients’ exposed time. However, NYP/CUMC EHR
data lacked this kind of longitudinal information relating to
when a patient was put on or taken off a medication. Our
prior study showed that insufficient confounder selection
led to high false positive rates [31] and therefore we
designed the two-step LASSO regression (step 1 of the
proposed methodological framework) to select more asso-
ciated confounders. The AUC performances were generally
improved after the confounding adjustment except for ALI.
We also applied this algorithm to the FAERS data and the
AUC performances were statistically significantly better
with this algorithm than without it. Although the proposed
confounding adjustment method for FAERS could not
leverage primary suspected information stemming from the
clinical judgment of the reporter, the results in electronic
supplementary material Table S3 show that the confound-
ing adjustment method achieved comparable performance
with the cutting-edge algorithm GPS based on primary
suspected medication. For example, the confounding
adjustment method had better AUC performances in ARF,
AMI, and GIB, and lower AUC performance in ALI. We
are also aware that clinical assessors in the industry
sometimes include concomitant medications in addition to
the primary suspected medication in the disproportionality
analysis. However, the implications of including con-
comitant medications in disproportionality analysis, which
is not able to deal with confounding by co-medication, are
beyond the scope of this paper. The advantage of the two-
step LASSO compared with the single LASSO is shown in
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electronic supplementary material Figure S1 and Figure S2,
where the two-step LASSO separated positive controls
more from negative ones, reduced the false positive rate,
and achieved better AUC performance.
4.6 False Positive Signals in CUMC/NYP EHR
One false positive signal was rosiglitazone for GIB.
Rosiglitazone was mentioned in the records of 1587
patients where 133 of the patients developed GIB. The
confounding adjustment method scored this pair with a
one-sided p value of 0.01. In contrast, pioglitazone is in the
same drug class, and was mentioned in the records of 2477
patients where 110 patients developed GIB. The con-
founding adjustment method scored this pair with a one-
sided p value of 1.
4.7 False Negative Signals in CUMC/NYP EHR
Ryan et al. demonstrated that the cohort method using
high dimensional features selected by Bayesian logistic
regression generally yielded a negatively biased estimate
[19]. We observed the same trend in our data set and
summarized possible reasons for false negative signals.
(1) Data sparseness since there were not enough patients
exposed to the studied medications when the ADR
occurrences were quite rare. (2) Confounding by indi-
cation because an indication for a drug may bias the
estimated association if it is associated with an increased
risk of the ADR itself. For example, amlodipine and
nifedipine have hypertension as an indication, but
hypertension was also related to AMI, and therefore the
method did not yield positive associations. However,
amlodipine and nifedipine were in the reference standard
as being positive for AMI. The proposed method could
not deal with this issue correctly, and more clinical
knowledge may be needed. For example, we may com-
pare a medication with the other medications in the same
treatment regimen to better understand its relationship
with the ADR.
4.8 Generalization of the Method
The overall method includes three steps, which are (1)
generating drug ADR signals, (2) calibrating ADR signal
scores based on a set of reference negatives, and (3) inte-
grating calibrated signals. Step 1 and Step 3 are easily
generalizable to other ADRs. Step 2 requires the avail-
ability of negative controls for a particular ADR, and for
ADRs where negative controls are available, the method is
generalizable. In addition, the process developed by
OMOP, which involves examining and collecting negative
controls, is generalizable and could be adapted to other
ADRs.
4.9 Limitations
This study had several limitations. First, using the NYP/
CUMC was a limitation because of its relatively small
population, which limited EHR signal detection capa-
bility, and therefore performance of the combined sys-
tem as well. In future work, we plan to include
additional EHR data from multiple sites. Second, when
using the NYP/CUMC EHR, we simply adopted the
OMOP outcome definitions, which may not be optimal
for the EHR data set, and could have led to outcome
misclassification including both false positive and false
negative patients. Third, the confounding adjustment
method did not deal well with drugs given only to a
particular patient population and therefore the control
groups on the basis of a general population were not
representative for that population. Fourth, the con-
founding adjustment method assumed a single and
homogeneous OR for a drug–ADR combination, which
may not be appropriate. For example, an ADR is more
likely to happen among patients who have contraindi-
cations or who have certain comorbidities than in other
patients. In future work, we plan to apply clustering
algorithms to group patients with similar symptoms or
diagnoses and then acquire associations within these
relatively homogeneous patient groups. Fifth, when
using FAERS, we did not remove duplicate reports or
correct terminological errors. Lastly, the reference stan-
dard consists of test cases that were publicly known
during the time frame of our evaluation, and thus the
performance may be altered when using the reference
standard of emerging safety signals [47].
5 Conclusions
In this paper, we described a method for ADR detection
that combined FAERS with healthcare data and showed
significant improvement when individual healthcare
resources had sufficient amounts of data. Although the
small NYP/CUMC EHR database did not contribute to
improvement, use of the large-size network-based GE EHR
data and claims data did significantly show improved
performance when combined with the FAERs data. An
advantage of this method is that it can serve as a tool for
synthesizing evidence for clinical assessors in actual
pharmacovigilance practice.
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